E16: Tocilizumab in Giant-Cell Arteritis - GIACTA
Getting back to our usual format, this week we'll discuss the GIACTA trial, which compared various schedules of tocilizumab to various schedules of placebo and prednisone. It's an important trial that has changed the face of GCA and will be a refreshing RCT to discuss before we dive back into garbagey data next week.
